Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-15

Clinical Trial Update: Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction [Phase 4]

View source ↗

Summary

Phase 4 trial update on the impact of eplerenone on cardiovascular outcomes after myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • eplerenone (eplerenone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Myocardial Infarction | Phase 4 | Status: COMPLETED | Results posted: 2016-08-15